FDA Reverses Position On Fabre-Kramer's Gepirone, Clearing Way For Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Dispute resolution win means focus for antidepressant Travivo (gepirone extended-release) shifts to labeling, post-marketing and manufacturing despite going 2 for 12 in clinical trials.
You may also be interested in...
20 Years After First FDA Filing, Gepirone Finally Approaches Depression Market
Private drug developer Fabre-Kramer is expecting approval for its antidepressant gepirone hydrochloride in September 2023. The drug has been rejected multiple times by the FDA as a treatment for major depressive disorder.
Dispute Resolution: Ardelyx Eyes Tenapanor Resubmission Following Successful Appeal To FDA
Office of New Drugs grants company’s appeal of complete response letter for tenapanor in dialysis patients, marking a rare sponsor victory through the agency’s formal dispute resolution process; new drug application resubmission is targeted for first half of 2023.
Biogen Aducanumab BLA Plan Is In Line With US FDA Neurology Division Precedent
Biogen and Eisai's surprise decision to advance Alzheimer’s antibody despite mixed clinical results could follow a similar path as pioneering neurodegenerative therapies Xenazine and Rilutek, or more recent Parkinson’s drug Nourianz – or could end with suspended development, like Kyndrisa.